

# VHA Prostate Measures

## Table of Contents

<b>Consultation and Work-Up .....</b>	<b>2</b>
Initial Evaluation (#A-1).....	2
Bone Imaging for High-Risk Disease (#A-2).....	3
Pelvic MRI Imaging (#A-3) <b>ASPIRATIONAL</b> .....	4
PET Imaging (#A-4) <b>SURVEILLANCE</b> .....	5
*Discussion of Treatment Options for Intermediate-Risk Disease (#A-5) .....	6
Multidisciplinary Consult Documentation (#A-6) .....	7
Quality of Life Assessment at Consult (#A-7).....	8
Active Surveillance (#A-8) <b>SURVEILLANCE</b> .....	9
<b>Simulation, Treatment Planning, and Treatment .....</b>	<b>10</b>
Pre-Treatment Preparation (#B-1).....	10
*Daily Target Localization (#B-2) .....	11
*Long term Androgen Deprivation Therapy for High-Risk Disease (#B-3).....	12
*Regional Nodal Radiation for High-Risk Disease (#B-4) .....	12
Acceptable Dose for Intact Prostate (#B-5) .....	13
*Patient Selection – Moderately Hypofractionated or Ultrahypofractionated (#B-6).....	14
Dose for Post-Prostatectomy (#B-7) .....	15
Genomic Classification (#B-8) <b>SURVEILLANCE</b> .....	15
<b>Follow-up .....</b>	<b>16</b>
Quality of Life Assessment at Follow-up (#C-1) <b>ASPIRATIONAL</b> .....	16
Baseline Bone Health Assessment (#C-2) .....	17

\*High Potential Impact Measure

## Consultation and Work-Up

Initial Evaluation (#A-1)	
<b>Numerator Statement</b>	Patients with documented evaluation, at the time of consult, that includes: <ol style="list-style-type: none"> <li>1. Prostate-specific antigen (PSA), <b>AND</b></li> <li>2. Primary <b>AND</b> Secondary Gleason score <b>OR</b> Gleason Grade Group, <b>AND</b></li> <li>3. NCCN risk group <b>AND</b></li> <li>4. Nodal status.</li> </ol>
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of prostate cancer.
<b>Exclusions/Exceptions</b>	<ul style="list-style-type: none"> <li>• Patients with metastatic disease.</li> <li>• Patients receiving palliative care.</li> </ul>
<b>Notes</b>	<ul style="list-style-type: none"> <li>• Previously Prostate Measure #2 (GU QM 2).</li> </ul>
<b>Expected Performance Rate</b>	Higher = Better. Expected Performance Rate: 90%
<b>Measure Type</b>	<input checked="" type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure

Bone Imaging for High-Risk Disease (#A-2)	
<b>Numerator Statement</b>	Patients with bone imaging performed prior to the initiation of treatment.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of high-risk <b>OR</b> very high-risk prostate cancer, as defined by NCCN, receiving radiation therapy to the primary disease site.
<b>Exclusions/Exceptions</b>	<ul style="list-style-type: none"> <li>• Patients receiving post-prostatectomy care.</li> </ul>
<b>Notes</b>	<ul style="list-style-type: none"> <li>• Examples of appropriate bone imaging are T<sup>99</sup> and NaF PET.</li> <li>• Previously a component of Prostate Measure #3 (GU QM 3).</li> </ul>
<b>Expected Performance Rate</b>	<p>Higher = Better.</p> <p>Expected Performance Rate: 90%</p> <p>CMS QPP Measure #102 (Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients).</p>
<b>Measure Type</b>	<input checked="" type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure

Pelvic MRI Imaging (#A-3) <b>ASPIRATIONAL</b>	
<b>Numerator Statement</b>	Patients with a pelvic MRI performed prior to the initiation of treatment.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of prostate cancer receiving radiation therapy to the primary disease site.
<b>Exclusions/Exceptions</b>	<ul style="list-style-type: none"> <li>• Patients with low-risk prostate cancer.</li> <li>• Patients receiving post-prostatectomy care.</li> <li>• Patients with a contraindication to MRI.</li> </ul>
<b>Notes</b>	<ul style="list-style-type: none"> <li>• Contraindication to MRI includes, but is not limited to: <ul style="list-style-type: none"> <li>○ Patients with a cardiovascular implantable electronic device (CIED) (e.g., pacemaker).</li> <li>○ Patients with metal objects in their body.</li> <li>○ Patients with claustrophobia or PTSD.</li> <li>○ Patients with severe obesity.</li> </ul> </li> <li>• Previously a component of Prostate Measure #3 (GU QM 3).</li> </ul>
<b>Expected Performance Rate</b>	Higher = Better. Expected Performance Rate: 75%
<b>Measure Type</b>	<input type="checkbox"/> Quality Measure <input checked="" type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure

PET Imaging (#A-4) <b>SURVEILLANCE</b>	
<b>Numerator Statement</b>	Patients with a PET scan performed prior to the initiation of treatment.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of prostate cancer <b>AND</b> post-prostatectomy <b>AND</b> biochemical failure receiving radiation therapy.
<b>Exclusions/Exceptions</b>	<ul style="list-style-type: none"> <li>Patients with known metastatic disease based on conventional imaging.</li> </ul>
<b>Notes</b>	None.
<b>Expected Performance Rate</b>	Higher = Better. Expected Performance Rate: N/A
<b>Measure Type</b>	<input type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input checked="" type="checkbox"/> Surveillance Measure

*Discussion of Treatment Options for Intermediate-Risk Disease (#A-5)	
<b>Numerator Statement</b>	<p>Patients who received counseling on treatment options, prior to initiation of treatment, that includes:</p> <ol style="list-style-type: none"> <li>1. External beam radiotherapy, <b>AND</b></li> <li>2. Brachytherapy, <b>AND</b></li> <li>3. Radical prostatectomy.</li> </ol>
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of intermediate-risk prostate cancer, as defined by NCCN, receiving radiation therapy to the primary disease site.
<b>Exclusions/Exceptions</b>	None.
<b>Notes</b>	<ul style="list-style-type: none"> <li>• Counseling on “radical prostatectomy” may be documented as discussion of surgery. This numerator requirement would be automatically met if the patient was previously seen by a urologist for prostatectomy consult/procedure.</li> <li>• Previously Prostate Measure #4 (GU QM 4).</li> <li>• <b>*High Potential Impact Measure</b></li> </ul>
<b>Expected Performance Rate</b>	<p>Higher = Better.</p> <p>Expected Performance Rate: 90%</p>
<b>Measure Type</b>	<input checked="" type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure

Multidisciplinary Consult Documentation (#A-6)	
<b>Numerator Statement</b>	<p>Patients with multidisciplinary consult, prior to the initiation of radiation treatment, demonstrated by:</p> <ol style="list-style-type: none"> <li>1. Discussion at multidisciplinary tumor board</li> </ol> <p style="text-align: center;"><b>OR</b></p> <ol style="list-style-type: none"> <li>2. Discussion with a urologist.</li> </ol>
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of clinically localized prostate cancer receiving radiation therapy to the primary disease site.
<b>Exclusions/Exceptions</b>	<ul style="list-style-type: none"> <li>• Patients receiving post-prostatectomy care.</li> </ul>
<b>Notes</b>	<ul style="list-style-type: none"> <li>• The “discussion with the urologist” may take place when reviewing test results for prostate cancer. The discussion must be related to the prostate cancer diagnosis and not other urinary issues (e.g., incontinence).</li> <li>• Clinically localized is defined as N0M0 disease.</li> </ul>
<b>Expected Performance Rate</b>	<p>Higher = Better.</p> <p>Expected Performance Rate: 90%</p>
<b>Measure Type</b>	<p><input checked="" type="checkbox"/> Quality Measure</p> <p><input type="checkbox"/> Aspirational Measure</p> <p><input type="checkbox"/> Surveillance Measure</p>

Quality of Life Assessment at Consult (#A-7)	
<b>Numerator Statement</b>	Patients with assessment of urinary <b>OR</b> bowel <b>OR</b> sexual <b>OR</b> hormonal domains using a validated instrument at the time of consult.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of prostate cancer receiving radiation therapy to the prostate or prostate resection bed.
<b>Exclusions/Exceptions</b>	None.
<b>Notes</b>	<ul style="list-style-type: none"> <li>• A validated instrument needs to be used (i.e., an internal assessment would not be sufficient), for example, acceptable instruments include: AUA, EPIC-CP, EPIC-26, IIEF/SHIM, PRO CTCAE, etc.</li> <li>• Previously Prostate Measure #5 (GU QM 5).</li> </ul>
<b>Expected Performance Rate</b>	Higher Score = Better. Expected Performance Rate: 90%
<b>Measure Type</b>	<input checked="" type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure



Active Surveillance (#A-8) <b>SURVEILLANCE</b>	
<b>Numerator Statement</b>	Patients with documentation of active surveillance as the treatment plan at the time of consult.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of very low-risk <b>OR</b> low-risk <b>OR</b> favorable intermediate-risk prostate cancer, as defined by NCCN.
<b>Exclusions/Exceptions</b>	None.
<b>Notes</b>	None.
<b>Expected Performance Rate</b>	Higher Score = Better. Expected Performance Rate: N/A (Surveillance Measure).
<b>Measure Type</b>	<input type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input checked="" type="checkbox"/> Surveillance Measure

## Simulation, Treatment Planning, and Treatment

Pre-Treatment Preparation (#B-1)	
<b>Numerator Statement</b>	<p>Patients with documentation of the following instructions prior to performing the simulation procedure:</p> <ol style="list-style-type: none"> <li>1. Rectal emptying <b>AND</b></li> <li>2. Bladder filling.</li> </ol>
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of prostate cancer receiving external beam radiation therapy to the primary disease site.
<b>Exclusions/Exceptions</b>	None.
<b>Notes</b>	<ul style="list-style-type: none"> <li>• This measure is inclusive of patients receiving radiation to the prostate or prostate bed.</li> <li>• Pre-treatment preparation instructions could be documented in a variety of locations, including but not limited to the simulation order, simulation instructions, or prescription.</li> </ul>
<b>Expected Performance Rate</b>	<p>Higher = Better.</p> <p>Expected Performance Rate: 90%</p>
<b>Measure Type</b>	<p><input checked="" type="checkbox"/> Quality Measure</p> <p><input type="checkbox"/> Aspirational Measure</p> <p><input type="checkbox"/> Surveillance Measure</p>

*Daily Target Localization (#B-2)	
<b>Numerator Statement</b>	Patients prescribed a daily target localization method before the start of radiation treatment.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of prostate cancer, receiving external beam radiation therapy to the primary disease site.
<b>Exclusions/ Exceptions</b>	None.
<b>Notes</b>	<ul style="list-style-type: none"> <li>• This measure is inclusive of patients receiving radiation to the prostate or prostate bed.</li> <li>• Examples of daily target localization include cone beam CT, CT on rails, fiducial markers with portal imaging (includes orthogonal/stereoscopic KV-KV or KV-MV imaging), electromagnetic transponder, transabdominal ultrasound, and transperineal ultrasound.</li> <li>• Previously Prostate Measure #11 (GU QM 11).</li> <li>• <b>*High Potential Impact Measure</b></li> </ul>
<b>Expected Performance Rate</b>	Higher = Better. Expected Performance Rate: 90%
<b>Measure Type</b>	<input checked="" type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure

*Long term Androgen Deprivation Therapy for High-Risk Disease (#B-3)	
<b>Numerator Statement</b>	Patients who are prescribed long term androgen deprivation therapy (ADT) neoadjuvant to <b>OR</b> concurrent with radiation therapy.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of high <b>OR</b> very high-risk prostate cancer, as defined by NCCN, receiving definitive radiation therapy to the primary disease site.
<b>Exclusions/Exceptions</b>	<ul style="list-style-type: none"> <li>Patients receiving post-prostatectomy care.</li> </ul>
<b>Notes</b>	<ul style="list-style-type: none"> <li>ADT examples include gonadotropin-releasing hormone [GnRH] agonist or antagonist.</li> <li>Long term is defined greater than or equal to 18 months.</li> <li>“Concurrent” is defined as +/- 2 weeks of the start of radiation therapy.</li> <li>Previously Prostate Measure #9 (GU QM 9).</li> <li><b>*High Potential Impact Measure</b></li> </ul>
<b>Expected Performance Rate</b>	Higher = Better. Expected Performance Rate: 90% CMS PQRS Measure #104 (Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients).
<b>Measure Type</b>	<input checked="" type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure

*Regional Nodal Radiation for High-Risk Disease (#B-4)	
<b>Numerator Statement</b>	Patients receiving regional pelvic nodal radiation.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of high <b>OR</b> very high-risk prostate cancer, as defined by NCCN, receiving definitive external beam radiation therapy to the primary disease site.
<b>Exclusions/Exceptions</b>	<ul style="list-style-type: none"> <li>Patients receiving post-prostatectomy care.</li> </ul>
<b>Notes</b>	<ul style="list-style-type: none"> <li>Previously Prostate Measure #12 (GU QM 12).</li> <li>The <b>regional pelvic lymph nodes</b> are located below the bifurcation of the common iliac arteries: the internal iliac <b>nodes</b> (including the sacral <b>nodes</b>) and the external iliac <b>nodes</b> (including the obturator <b>nodes</b>).</li> <li><b>*High Potential Impact Measure</b></li> </ul>
<b>Expected Performance Rate</b>	Higher = Better. Expected Performance Rate: 90%
<b>Measure Type</b>	<input checked="" type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure

Acceptable Dose for Intact Prostate (#B-5)	
<b>Numerator Statement</b>	<p>Patients prescribed a course of treatment to the prostate PTV with an acceptable dose fraction regimen, including:</p> <ul style="list-style-type: none"> <li>○ 800 cGy x 5 fractions <b>OR</b></li> <li>○ 750 cGy x 5 fractions <b>OR</b></li> <li>○ 725 cGy x 5 fractions <b>OR</b></li> <li>○ 700 cGy x 5 fractions <b>OR</b></li> <li>○ 610 cGy x 7 fractions <b>OR</b></li> <li>○ 300 cGy x 20 fractions <b>OR</b></li> <li>○ 270 cGy x 26 fractions <b>OR</b></li> <li>○ 250 cGy x 28 fractions <b>OR</b></li> <li>○ 240 cGy x 30 fractions <b>OR</b></li> <li>○ 200 cGy x 37 fractions <b>OR</b></li> <li>○ 200 cGy x 38 fractions <b>OR</b></li> <li>○ 200 cGy x 39 fractions <b>OR</b></li> <li>○ 180 cGy x 42 fractions <b>OR</b></li> <li>○ 180 cGy x 43 fractions <b>OR</b></li> <li>○ 180 cGy x 44 fractions.</li> </ul>
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of prostate cancer receiving definitive external beam radiation therapy.
<b>Exclusions/Exceptions</b>	<ul style="list-style-type: none"> <li>• Patients receiving post-prostatectomy care.</li> <li>• Patients with recurrent disease.</li> <li>• Patients with metastatic disease.</li> <li>• Patients receiving pelvic lymph node radiation.</li> <li>• Patients receiving combined brachytherapy.</li> <li>• Patients on a clinical trial.</li> </ul>
<b>Notes</b>	None.
<b>Expected Performance Rate</b>	<p>Higher = Better.</p> <p>Expected Performance Rate: 90%</p>
<b>Measure Type</b>	<input checked="" type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure

<b>*Patient Selection – Moderately Hypofractionated or Ultrahypofractionated (#B-6)</b>	
<b>Numerator Statement</b>	Patients prescribed a moderately <b>OR</b> ultrahypofractionated regimen.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of prostate cancer receiving definitive external beam radiation therapy.
<b>Exclusions/Exceptions</b>	<ul style="list-style-type: none"> <li>• Patients receiving post-prostatectomy care.</li> <li>• Patients with recurrent disease.</li> <li>• Patients with metastatic disease.</li> <li>• Patients receiving pelvic lymph node radiation.</li> <li>• Patients receiving combined brachytherapy.</li> <li>• Patients on a clinical trial.</li> </ul>
<b>Notes</b>	<ul style="list-style-type: none"> <li>• Moderately hypofractionated regimen is defined as treatments where the dose per fraction is <math>\geq 240</math> cGy and <math>\leq 340</math> cGy.</li> <li>• Ultrahypofractionated regimen is defined as treatments where the dose per fraction is <math>\geq 500</math> cGy.</li> <li>• <b>*High Potential Impact Measure</b></li> </ul>
<b>Expected Performance Rate</b>	Higher = Better. Expected Performance Rate: 90%
<b>Measure Type</b>	<input checked="" type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure

Dose for Post-Prostatectomy (#B-7)	
<b>Numerator Statement</b>	Patients prescribed a total dose $\geq 6400$ cGy and $\leq 7200$ cGy at 180-200 cGy/fraction to the prostate resection bed.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of prostate cancer receiving external beam radiation therapy after a prostatectomy.
<b>Exclusions/Exceptions</b>	<ul style="list-style-type: none"> <li>• Patients with gross disease in the prostate resection bed.</li> <li>• Patients on a clinical trial.</li> </ul>
<b>Notes</b>	<ul style="list-style-type: none"> <li>• Previously Prostate Measure #15.</li> </ul>
<b>Expected Performance Rate</b>	Higher = Better. Expected Performance Rate: 90%
<b>Measure Type</b>	<input checked="" type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure

Genomic Classification (#B-8) <b>SURVEILLANCE</b>	
<b>Numerator Statement</b>	Patients with documentation of genomic classification prior to the initiation of radiation or hormonal treatment.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of prostate cancer who received definitive treatment to the prostate or prostate resection bed.
<b>Exclusions/Exceptions</b>	None.
<b>Notes</b>	None.
<b>Expected Performance Rate</b>	Expected Performance Rate: N/A (Surveillance Measure).
<b>Measure Type</b>	<input type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input checked="" type="checkbox"/> Surveillance Measure

## Follow-up

Quality of Life Assessment at Follow-up (#C-1) <b>ASPIRATIONAL</b>	
<b>Numerator Statement</b>	Patients with assessment of urinary <b>OR</b> bowel <b>OR</b> sexual <b>OR</b> hormonal domains using a validated instrument at every follow-up.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of prostate cancer who have completed radiation therapy to the prostate or prostate resection bed who have a follow-up visit.
<b>Exclusions/Exceptions</b>	None.
<b>Notes</b>	<ul style="list-style-type: none"> <li>• A validated instrument needs to be used (i.e., an internal assessment would not be sufficient). For example, acceptable instruments include: AUA, EPIC-26, IIEF/SHIM, PRO CTCAE, etc.</li> <li>• Measure is to be assess at each follow-up visit; therefore, a single patient may be assessment multiple times.</li> <li>• Previously Prostate Measure #19.</li> </ul>
<b>Expected Performance Rate</b>	Higher = Better. Expected Performance Rate: 90%
<b>Measure Type</b>	<input type="checkbox"/> Quality Measure <input checked="" type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure



Baseline Bone Health Assessment (#C-2)	
<b>Numerator Statement</b>	Patients with a bone density assessment within +/- 3 months of the start of hormonal therapy.
<b>Denominator Statement</b>	All patients, regardless of age, with a diagnosis of prostate cancer prescribed long term androgen deprivation therapy (ADT).
<b>Exclusions/Exceptions</b>	None.
<b>Notes</b>	<ul style="list-style-type: none"> <li>• ADT examples include gonadotropin-releasing hormone [GnRH] agonist or antagonist.</li> <li>• The timing of the bone density assessment can be between 3 months before and 3 months after initiating hormonal therapy.</li> <li>• Previously Prostate Measure #24.</li> <li>• Long term is defined greater than or equal to 18 months.</li> </ul>
<b>Expected Performance Rate</b>	Higher = Better. Expected Performance Rate: 90%
<b>Measure Type</b>	<input checked="" type="checkbox"/> Quality Measure <input type="checkbox"/> Aspirational Measure <input type="checkbox"/> Surveillance Measure